Context Therapeutics Inc.
Clinical trials sponsored by Context Therapeutics Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug CT-95 targets tough cancers in early trial Results expected Dec 2026 (estimated)
-
New antibody takes aim at Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called CTIM-76 in people with advanced ovarian, testicular, or endometrial cancers that have not responded to standard treatments. CTIM-76 is a bispecific antibody designed to attach to a protein called Claudin-6 on cancer cells and he…
Phase 1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called CT-202 in people with advanced triple-negative breast cancer, colorectal cancer, or bladder cancer that has come back or spread. The drug is a bispecific antibody designed to help the immune system attack cancer cells that have a pro…
Phase 1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug CT-95 targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…
Phase 1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC